← Back to Search

Antibacterial Agent

Neosporin for COVID-19

Phase 1
Waitlist Available
Led By Charles Dela Cruz, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to month 1
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions

Summary

This trial is testing if applying Neosporin inside the nose can boost natural virus-fighting proteins in healthy people. This could help protect against COVID-19, especially for those without vaccine access or who are hesitant to get vaccinated.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to month 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to month 1 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biological Assay
Change in RNA expression profile of ISGs using single cell RNAseq assay
Change in in interferon response gene expression profile from nasal samples collected measured by RT-PCR
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NeosporinExperimental Treatment1 Intervention
Neosporin will be distributed by the Yale Investigational Pharmacy. Subjects are to use Neosporin twice a day for 7 days.
Group II: Vaseline or equivalentPlacebo Group1 Intervention
Vaseline or equivalent will be distributed by the Yale Investigational Pharmacy. Subjects are to use Vaseline twice a day for 7 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neomycin
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bill and Melinda Gates FoundationOTHER
415 Previous Clinical Trials
22,956,882 Total Patients Enrolled
15 Trials studying COVID-19
96,771 Patients Enrolled for COVID-19
Yale UniversityLead Sponsor
1,924 Previous Clinical Trials
3,031,615 Total Patients Enrolled
31 Trials studying COVID-19
541,891 Patients Enrolled for COVID-19
Charles Dela Cruz, MDPrincipal InvestigatorYale University

Media Library

Neosporin (Antibacterial Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05449392 — Phase 1
COVID-19 Research Study Groups: Neosporin, Vaseline or equivalent
COVID-19 Clinical Trial 2023: Neosporin Highlights & Side Effects. Trial Name: NCT05449392 — Phase 1
Neosporin (Antibacterial Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05449392 — Phase 1
~21 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top